News | 16 August 2012
Rumors in investing circles began spreading earlier this week that the firm that specializes in biotech could be the target of a takeover by a larger pharmaceutical firm. Whether or not this speculation will amount to anything in the long term remains ...
Click on the link to read the full article at Kapitall Blog (blog)
(This link will open in a new window)